AR045768A1 - Compuestos de cefem y sus sales farmaceuticamente aceptables - Google Patents

Compuestos de cefem y sus sales farmaceuticamente aceptables

Info

Publication number
AR045768A1
AR045768A1 ARP040103366A ARP040103366A AR045768A1 AR 045768 A1 AR045768 A1 AR 045768A1 AR P040103366 A ARP040103366 A AR P040103366A AR P040103366 A ARP040103366 A AR P040103366A AR 045768 A1 AR045768 A1 AR 045768A1
Authority
AR
Argentina
Prior art keywords
independently
protected
amino
pharmaceutically acceptable
formula
Prior art date
Application number
ARP040103366A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003905084A external-priority patent/AU2003905084A0/en
Application filed by Fujisawa Pharmaceutical Co, Wakunaga Pharma Co Ltd filed Critical Fujisawa Pharmaceutical Co
Publication of AR045768A1 publication Critical patent/AR045768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Un procedimiento para preparar un compuesto de la fórmula (1), y una composición farmacéutica que comprende un compuesto de la fórmula (1) en mezcla con un portador farmacéuticamente aceptable. Reivindicación 1: Un compuesto cefem caracterizado porque tiene la fórmula (1), en donde: R1 es alquilo inferior o hidroxialquilo (inferior); y R2 es hidrógeno o grupo de protección amino; o R1 y R2 están unidos entre sí y forman alquileno inferior; R3 es -A-R6, en donde: A es un enlace, -NHCO- (CH2CO)n-, en donde n es 0 ó 1, alquileno inferior, -NH-CO-CO- o una fórmula (2), y R6 es un grupo de fórmulas (3), en donde: Z1 y Z2 son, de modo independiente, -NHCO- o -CONH-, k, q y r son, de modo independiente, 0 ó 1; s y t son, de modo independiente, un número entero de 0 a 6; m y p son, de modo independiente, un número entero de 0 a 6; y R7, R8, R9 y R10 son, de modo independiente, amino, amino protegido, guanidino, guanidino protegido, amidino o amidino protegido; R4 es carboxi o carboxi protegido; y R5 es amino o amino protegido, o una de sus sales farmacéuticamente aceptables.
ARP040103366A 2003-09-18 2004-09-17 Compuestos de cefem y sus sales farmaceuticamente aceptables AR045768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003905084A AU2003905084A0 (en) 2003-09-18 Cephem Compounds

Publications (1)

Publication Number Publication Date
AR045768A1 true AR045768A1 (es) 2005-11-09

Family

ID=34318291

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103366A AR045768A1 (es) 2003-09-18 2004-09-17 Compuestos de cefem y sus sales farmaceuticamente aceptables

Country Status (13)

Country Link
US (1) US7192943B2 (es)
EP (1) EP1663245B1 (es)
JP (1) JP4643577B2 (es)
KR (1) KR20060069475A (es)
CN (1) CN1852715A (es)
AR (1) AR045768A1 (es)
AT (1) ATE463248T1 (es)
CA (1) CA2536636A1 (es)
DE (1) DE602004026451D1 (es)
ES (1) ES2340928T3 (es)
MX (1) MXPA06003068A (es)
TW (1) TW200524943A (es)
WO (1) WO2005027909A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446099A1 (en) * 2001-05-01 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP1556389B9 (en) * 2002-10-30 2015-09-09 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US20090012054A1 (en) * 2006-03-16 2009-01-08 Astellas Pharma Inc. Cephem Compounds and Use as Antimicrobial Agents
EP2021316A1 (en) * 2006-05-26 2009-02-11 Abbott Laboratories Inhibitors of polo-like kinases
EP3616695A1 (en) 2011-09-09 2020-03-04 Merck Sharp & Dohme Corp. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9006421B2 (en) 2013-03-14 2015-04-14 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US20140274996A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Tazobactam and ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274989A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Manufacturing beta-lactam combination products
ES2800603T3 (es) 2013-09-09 2021-01-04 Merck Sharp & Dohme Tratamiento de infecciones con ceftolozano/tazobactam en sujetos con insuficiencia renal
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015196077A1 (en) * 2014-06-20 2015-12-23 Merck Sharp & Dohme Corp. Reactions of thiadiazolyl-oximinoacetic acid derivative compounds
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
CN110204558B (zh) 2014-08-15 2022-05-06 默沙东公司 头孢菌素化合物的合成
WO2016028670A1 (en) 2014-08-18 2016-02-25 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
US10035774B2 (en) 2014-12-18 2018-07-31 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
US10059680B2 (en) 2014-12-18 2018-08-28 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
US10214543B2 (en) 2014-12-30 2019-02-26 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (es) 1980-09-12 1984-09-26 Ciba Geigy Ag
JPS584789A (ja) * 1981-04-03 1983-01-11 Fujisawa Pharmaceut Co Ltd 新規セフエム化合物およびその製造法
EP0062321B1 (en) * 1981-04-03 1989-03-01 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8805642D0 (en) * 1988-03-09 1988-04-07 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
JPH03255087A (ja) * 1990-03-05 1991-11-13 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物およびその塩類
CN1150429A (zh) * 1994-05-23 1997-05-21 韩国科学技术研究院 头孢菌素化合物及其制备方法
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
CA2446099A1 (en) * 2001-05-01 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP1556389B9 (en) * 2002-10-30 2015-09-09 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds

Also Published As

Publication number Publication date
JP4643577B2 (ja) 2011-03-02
US20050096306A1 (en) 2005-05-05
US7192943B2 (en) 2007-03-20
TW200524943A (en) 2005-08-01
WO2005027909A1 (en) 2005-03-31
EP1663245B1 (en) 2010-04-07
CA2536636A1 (en) 2005-03-31
DE602004026451D1 (de) 2010-05-20
ES2340928T3 (es) 2010-06-11
EP1663245A1 (en) 2006-06-07
MXPA06003068A (es) 2006-08-25
KR20060069475A (ko) 2006-06-21
JP2007505895A (ja) 2007-03-15
ATE463248T1 (de) 2010-04-15
CN1852715A (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
AR045768A1 (es) Compuestos de cefem y sus sales farmaceuticamente aceptables
AR041729A1 (es) Compuesto de cefemo
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
BG106013A (en) New compounds and compositions as protease inhibitors
DK0749424T3 (da) Naphthalenderivater som prostaglandin-I2-agonister
CO6241190A2 (es) Compuestos para inhibicion enzimatica
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
AP2001002241A0 (en) Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
HUP0302825A2 (hu) Lipidben gazdag plakkok csökkentésére szolgáló szerek
HUP9902410A2 (hu) Amidinszármazékok, előállításuk, trombininhibitorként való alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
AR033300A1 (es) Compuestos de cefem
AR040473A1 (es) Derivados de aminoalcoholes, un procedimiento de preparacion, composicion farmaceutica y uso del compuesto para preparar medicamentos
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
MY136824A (en) Substituted benzoxazinones and uses thereof
AR044175A1 (es) Compuestos de cefemo
MXPA04000443A (es) Metodo novedoso para la sintesis de derivados del acido (2s, 3as, 7as)-1-[(s)-alanil]-octahidro-1h-indol-2-carboxilico y la aplicacion en la sintesis de perindopril.
CO5160261A1 (es) Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
IL181888A0 (en) Aminoalcohol derivatives and pharmaceutical compositions containing the same
MXPA02007973A (es) Compuestos de aminoacidos y su uso como inhibidores de nep, ace y ece.
TR200401488T4 (tr) CNS bozukluklarının tedavisinde faydalı indol türevleri
BR0013375A (pt) Composições farmacêuticas contendo derivados tiazolidinodiona e processo para sua preparação
ATE377017T1 (de) Verbindungen, die faktor xa-aktiv t inhibieren
AR026936A1 (es) Compuestos heterociclicos y composiciones que los contienen
GEP20084296B (en) Novel 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FB Suspension of granting procedure